STOCK TITAN

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NRx Pharmaceuticals (NASDAQ: NRXP) has rescheduled its third quarter and year to date 2024 financial results conference call to Monday, November 18, 2024, at 4:30 PM ET. The change was made to accommodate potential additional corporate news. Investors can access the conference call through a live webcast on the company's website or via telephone using domestic (+1-800-717-1738) or international (+1-646-307-1865) dial-in numbers.

NRx Pharmaceuticals (NASDAQ: NRXP) ha riprogrammato la sua conference call sui risultati finanziari del terzo trimestre e dell'anno fino ad oggi 2024 per lunedì 18 novembre 2024, alle 16:30 ET. Il cambiamento è stato effettuato per consentire eventuali ulteriori comunicazioni aziendali. Gli investitori possono accedere alla conference call tramite un webcast dal vivo sul sito web dell'azienda o tramite telefono utilizzando i numeri di accesso nazionali (+1-800-717-1738) o internazionali (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP) ha reprogramado su conferencia telefónica sobre los resultados financieros del tercer trimestre y del año hasta la fecha de 2024 para el lunes 18 de noviembre de 2024, a las 4:30 PM ET. El cambio se realizó para acomodar posibles noticias corporativas adicionales. Los inversores pueden acceder a la conferencia a través de una transmisión en vivo en el sitio web de la empresa o por teléfono utilizando los números de marcado nacional (+1-800-717-1738) o internacional (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP)는 2024년 3분기 및 연간 재무 결과에 대한 컨퍼런스 콜을 2024년 11월 18일 월요일 오후 4시 30분 ET로 재조정했습니다. 이 변경은 추가 기업 뉴스에 대한 수용을 위해 이루어졌습니다. 투자자들은 회사 웹사이트의 실시간 웹캐스트를 통해 또는 국내 (+1-800-717-1738) 및 국제 (+1-646-307-1865) 전화 접속 번호를 사용하여 컨퍼런스 콜에 접속할 수 있습니다.

NRx Pharmaceuticals (NASDAQ: NRXP) a reprogrammé sa conférence téléphonique sur les résultats financiers du troisième trimestre et de l'année en cours 2024 pour le lundi 18 novembre 2024 à 16h30 ET. Ce changement a été effectué pour permettre d'éventuelles actualités corporatives supplémentaires. Les investisseurs peuvent accéder à la conférence téléphonique via un webinaire en direct sur le site web de l'entreprise ou par téléphone en utilisant les numéros d'appel nationaux (+1-800-717-1738) ou internationaux (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP) hat die Telefonkonferenz zu den Finanzresults des dritten Quartals und des laufenden Jahres 2024 auf Montag, den 18. November 2024, um 16:30 Uhr ET verschoben. Die Änderung wurde vorgenommen, um mögliche zusätzliche Unternehmensnachrichten zu berücksichtigen. Investoren können auf die Telefonkonferenz über ein Live-Webcast auf der Unternehmenswebsite oder telefonisch über nationale (+1-800-717-1738) oder internationale (+1-646-307-1865) Einwahlnummern zugreifen.

Positive
  • None.
Negative
  • None.

WILMINGTON, Del., Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news.

A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.  

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-reschedules-conference-call-to-discuss-third-quarter-and-year-to-date-2024-financial-results-to-november-18-2024-302303897.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When is NRx Pharmaceuticals (NRXP) Q3 2024 earnings call?

NRx Pharmaceuticals has rescheduled its Q3 2024 earnings call to Monday, November 18, 2024, at 4:30 PM ET.

How can I access NRXP's Q3 2024 earnings call?

You can access the call through a live webcast at https://ir.nrxpharma.com/events or by phone at +1-800-717-1738 (domestic) or +1-646-307-1865 (international).

Why did NRXP reschedule its Q3 2024 earnings call?

NRx Pharmaceuticals rescheduled the conference call to accommodate potential additional corporate news.

NRX Pharmaceuticals, Inc.

NASDAQ:NRXP

NRXP Rankings

NRXP Latest News

NRXP Stock Data

13.89M
10.75M
26.51%
4.75%
5.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON